福莫特罗和ICI118551对大鼠成熟破骨细胞骨吸收功能的影响
|
摘要
[目的]:骨质疏松尤其是绝经后骨质疏松是常见老年性疾病,易造成骨折等相关并发症,对个人和社会造成的危害巨大。近年来相关基础研究也有很多新的进展,发现交感神经系统对骨代谢的调节作用是近年来在骨代谢研究方面取得的成就之一。瘦素-交感神经系统对骨代谢的影响是近年来研究的热点,瘦素可通过激活中枢下丘脑神经元,继而激活外周交感神经系统,再通过激活骨组织细胞表面的β2肾上腺素能受体而抑制骨形成。本实验通过研究选择性β2肾上腺素能受体激动剂福莫特罗(Formoterol)和选择性β2肾上腺素能受体阻滞剂ICI118551对体外大鼠成熟破骨细胞(osteoclast,OC)功能的影响,探讨β2肾上腺素能受体信号对骨代谢的影响。
[方法]:取清洁级出生24h内的SD乳大鼠,长骨干骨髓腔内壁机械分离成熟OC后分别加入不同浓度(1×10~(-5)mol/L,1×10~(-6)mol/L,1×10~(-7)mol/L,1×10~(-8)mol/L,1×10-9mol/L)的Formoterol和ICI118551,以抗酒石酸酸性磷酸酶(TRAP)染色法观察破骨细胞形态,甲苯胺蓝染色法在100和250倍倒置相差显微镜下观察计数并拍照骨片上的骨吸收陷窝,Image-Pro Plus 6.0图像软件分析骨片上骨吸收陷窝面积。
[结果]:破骨细胞与骨片共培养6天,Formoterol在1×10~(-5)mol/L～1×10~(-9)mol/L浓度时与空白对照组比明显增加骨片上OC的骨吸收陷窝数目和面积; ICI118551在1×10~(-5)mol/L～1×10~(-9)mol/L浓度时与空白对照组相比明显降低骨片上骨吸收陷窝的数目和面积,且随着ICI118551浓度的提高骨吸收陷窝的数目和面积逐渐减小。
[结论]:β2肾上腺素能受体激动剂可促进体外培养OC的骨吸收功能,阻滞剂对OC的骨吸收功能有抑制作用。
【Objectives】: To evaluate the effects of Formoterol (β2-adrenergic receptor-specific agonist) and ICI118551 (β2-adrenergic receptor-specific antagonist) on rat matured ostoeclast cells in vitro.
【Methods】: Mature OC were isolated directly from neonatal 24-hour-SD rat long bones. The OC was treated with different concentrations of Formoterol and ICI118551 from 10~(-5)mol/L～10~(-9)mol/L respectively. Then the OC was stained with tartrate-resistant acid phosphatase (TRAP) to observe cellular morphology. The bone slices were stained with toluidine blue to count the number of the bone resorption pits and analyse the bone resorption pits by Image-Pro Plus 6.0.
【Results】: The number and area of the bone resorption pits increased in different concentrations of Formoterol treatment compared that in control treatment after osteoclasts and bone slices co-cultured for 6 days. Furthermore, the number and area of the bone resorption pits decreased with the dose of ICI118551increased gradually.
【Conclusions】: Theβ2-adrenergic receptor-specific agonist could promote the bone absorbion of OC in vitro. Theβ2-adrenergic receptor-specific antagonist inhibits the bone resorption of OC in a dose-dependent manner.
[方法]:取清洁级出生24h内的SD乳大鼠,长骨干骨髓腔内壁机械分离成熟OC后分别加入不同浓度(1×10~(-5)mol/L,1×10~(-6)mol/L,1×10~(-7)mol/L,1×10~(-8)mol/L,1×10-9mol/L)的Formoterol和ICI118551,以抗酒石酸酸性磷酸酶(TRAP)染色法观察破骨细胞形态,甲苯胺蓝染色法在100和250倍倒置相差显微镜下观察计数并拍照骨片上的骨吸收陷窝,Image-Pro Plus 6.0图像软件分析骨片上骨吸收陷窝面积。
[结果]:破骨细胞与骨片共培养6天,Formoterol在1×10~(-5)mol/L～1×10~(-9)mol/L浓度时与空白对照组比明显增加骨片上OC的骨吸收陷窝数目和面积; ICI118551在1×10~(-5)mol/L～1×10~(-9)mol/L浓度时与空白对照组相比明显降低骨片上骨吸收陷窝的数目和面积,且随着ICI118551浓度的提高骨吸收陷窝的数目和面积逐渐减小。
[结论]:β2肾上腺素能受体激动剂可促进体外培养OC的骨吸收功能,阻滞剂对OC的骨吸收功能有抑制作用。
【Objectives】: To evaluate the effects of Formoterol (β2-adrenergic receptor-specific agonist) and ICI118551 (β2-adrenergic receptor-specific antagonist) on rat matured ostoeclast cells in vitro.
【Methods】: Mature OC were isolated directly from neonatal 24-hour-SD rat long bones. The OC was treated with different concentrations of Formoterol and ICI118551 from 10~(-5)mol/L～10~(-9)mol/L respectively. Then the OC was stained with tartrate-resistant acid phosphatase (TRAP) to observe cellular morphology. The bone slices were stained with toluidine blue to count the number of the bone resorption pits and analyse the bone resorption pits by Image-Pro Plus 6.0.
【Results】: The number and area of the bone resorption pits increased in different concentrations of Formoterol treatment compared that in control treatment after osteoclasts and bone slices co-cultured for 6 days. Furthermore, the number and area of the bone resorption pits decreased with the dose of ICI118551increased gradually.
【Conclusions】: Theβ2-adrenergic receptor-specific agonist could promote the bone absorbion of OC in vitro. Theβ2-adrenergic receptor-specific antagonist inhibits the bone resorption of OC in a dose-dependent manner.
引文
[1] Elefteriou F,Ahn JD,Takeda S, et al. Leptin regulation of bone resorptionby the sympathetic nervous systemand CART[J]. Nature.2005;434(7032):514-520.
[2] Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system[J]. Cell. 2002; 111(3):305-317.
[3] Chambers T, Magnus C. Calcitonin alters behavior of isolated osteoclasts[J]. J Pathol.1982;136(1):27-39.
[4]李斌斌,于世凤,庞淑珍.两种破骨细胞培养方法的比较及其吸收骨质的动态观察[J].北京大学学报(医学版). 2005; 37(5):536-541.
[5] Takeuchi T,Tsuboi T,Arai M, et al. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells[J]. Biochemical Pharmacology. 2001;61(5):579-586.
[6] Roodman G. Cell biology of the osteoclast[J]. Exp Hematol,1999,27:1229-1241.
[7] Zhao Q, Shao J, Chen W,et al. Osteoclast differentiation and gene regulation. Front Biosci. 2007;12:2519-2529.
[8]赵媛,王正东.骨组织工程种子细胞的研究及应用进展.沈阳医学院学报.2007,9(1):56-59.
[9] Gangji V, Hauzeur J, Schoutens A,et al. Abnormalities in the replicative capacity of osteoblastic cells in the proximal femur of patients with osteonecrosis of the femoral head. J Rheumatol.2003,30(2):348-351.
[10] Hofbauer L, Dunstan C, Spelsberg T,et al. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun.1998;250 (3):776-781
[11] Thirunavukkarasu K, Miles R, Halladay D, Stimulation of osteoprotegerin (OPG)gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem.2001;276 (39):36241-36250.
[12] Lee S, Lorenzo J. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology.1999;140 (8):3552-3561.
[13] Ma Y, Cain R, Halladay D,et al. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology.2001;142 (9):4047-4054.
[14] Amano S, Arai M, Goto S,et al. Inhibitory effect of NPY on isoprenaline-induced osteoclastogenesis in mouse bone marrow cells. Biochim Biophys Acta. 2007; 1770(6):966-973.
[15] Kaczmarczyk-Sedlak I, Janiec W. Effects of catecholamines on blood pressure in the long bone marrow cavity in rats with bisphosphonate-induced osteopetrosis. Pharmacol Rep.2005;57(5):623-634.
[16] Kondo H, Nifuji A, Takeda S,et al. Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system. J Biol Chem.2005;280 (34):30192-30200.
[17] Ishizuka K, Hirukawa K, Nakamura H,et al. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. Neurosci Lett.2005,379(1):47-51.
[18] Bab I, Zimmer A. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol.2008 Jan;153(2):182-188.
[19] Bab I. Regulation of skeletal remodeling by the endocannabinoid system. Ann NY Acad Sci. 2007; 1116:414-422.
[20] Bonnet N,Laroche N,Vico L,et al.Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats. J Pharmacol Exp Ther.2006;318 (3):1118-1127.
[21] Togari A. Increased bone resorption by sympathetic nervous activity. Clin Calcium.2006;16(2):298-303.
[22] Cohen MM Jr. Role of leptin in regulating appetite, neuroendocrine function, and bone remodeling. Am J Med Genet A.2006;140(5):515-24.
[23] Tam J, Ofek O, Fride E,et al. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol.2006;70(3):786 -92.
[24] Pogoda P, Egermann M, Schnell J,et al. Leptin inhibits bone formation not only in rodents, but also in sheep. J Bone Miner Res.2006;21(10):1591-1599.
[25] Kim J, Jeong D, Kang H,et al. Osteoclast precursors display dynamic metabolic shifts toward accelerated glucose metabolism at an early stage of RANKL- stimulated osteoclast differentiation. Cell Physiol Biochem.2007;20(6):935-946.
[26] Lorenzo J. Osteoclast precursor cells. Adv Exp Med Biol.2007; 602:77-82.
[27] Moore R,Smith C,Bailey C,et al.Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture[J].Bone Miner, 1993;23:301-315.
[28] Kellenberger S, Muller K, Richener H,et al.Formoterol and isoproterenol induce c-fos gene expression in osteoblast-like cells by activating beta-adrnergic receptors[J]. Bone,1998;22(5):471-478.
[29] Bjurholm A, Kreicbergs A, Schultzberg M, Lerner UH. Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106-01, ROS 17/2.8, MC3T3-E1, and Saos-2) and primary bone cells[J].Bone Miner Res.1992;7(9):1011-1009.
[30] Greenfield E, Horowitz M, Lavish S. Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction[J].Biol Chem. 1996;271(18):10984-10989.
[31] Aitken S, Landao-Bassonga E, Ralston S, et al.β2-Adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms [J].Arch Biochem Biophys. 2009;482(1-2):96-103.
[32] Ducy P, Amling M, Takeda S et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass[J].Cell.2000;100(2):197-207.
[33] Arai M, Nagasawa T, Koshihara Y, et al. Effects ofβ-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells[J].Biochim Biophys Acta. 2003;1640(2-3):137-142.
[34] Bonnet N, Gadois C, McCloskey E,et al.Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture[J].Bone.2007;40(5):1209-1216.
[35] Pasco J, Henry M, Sanders K, et al. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density[J]. J Bone Miner Res. 2004; 19(1):19-24.
[36] Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study[J]. J Hypertens. 2006 ; 24(3):581-189.
[37] Schlienger R, Kraenzlin M, Jick S,et al. Use of beta-blockers and risk of fractures[J].JAMA. 2004; 292(11):1326-1332.
[38] Reid I, Gamble G, Grey A,et al.Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures[J].J Bone Miner Res.2005;20(4):613–618.
[1] Roodman G. Cell biology of the osteoclast[J]. Exp Hematol,1999,27:1229-1241.
[2] Zhao Q, Shao J, Chen W,et al. Osteoclast differentiation and gene regulation. Front Biosci. 2007;12:2519-29.
[3] Roberto Pacifici. Editorial:Cytokines, Estrogen,and Postmenopausal Osteoporosis -The Second Decade [J]. Endocrinology,1998,139(6):2659-2661.
[4] Udagawa N, Takahashi N, Akatsu T,et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A. 1990,87(18):7260-4.
[5] Jimi E,Nakamura I,Amano H,et al. Oeteoclast functions is activated by osteoblastic cells through a mechanism involving cell-to-cell contact [J]. Endocrinology,1996,137(5):2187～2190.
[6] Lacey D, Timms E, Tan H,et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.Cell,1998,93(2):309-319.
[7] Simonet W, Lacey D, Dunstan C,et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell,1997,89(2):309-19.
[8] Hofbauer L, Schoppet M.Clinical implications of the osteoprotegering/RANKL/RANK system for bone and vascular diseases. JAMA, 2004,292(4):490-5.
[9] Ramalho A, Jullienne A, Couttet P,et al. Effect of ostradiol on cytokine production in immortalized human marrow stromal cell lines. Cytokine. 2001,16 (4):126-30.
[10] Udagawa N. The mechanism of osteoclast differentiation from macrophages: possible roles of T lymphocytes in osteoclastogenesis. J Bone Miner Metab.2003; 21(6):337-43.
[11] Lee S, Lorenzo J. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation . Endocrinology.1999, 140(8): 3552-61.
[12] Kitazawa R,Kitazawa S, Maeda S. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene . Biochim Biophys Acta .1999,1445(1): 134-41.
[13] Rodan S, Rodan G. Integrin function in osteoclasts. J Endocrinol, 1997, 154: S47-S56.
[14] Vaananen H, Horton M.The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J Cell Sci.1995,108 ( Pt 8):2729-32.
[15] Stenbeck G, Horton M.A new specialized cell-matrix interaction in actively resorbing osteoclasts. J Cell Sci. 2000,113 ( Pt 9):1577-87.
[16] Schlesinger P, Blair H, Teitelbaum S, et al.Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption. J Biol Chem. 1997,272(30):18636-43.
[17] Xiong W, Feng X. PYK2 and FAK in osteoclasts. Front Biosci. 2003,8: d1219-1226.
[18] Singh A, Kaur A, Anand N,et al. Pyknodysostosis: visceral manifestations and simian crease. Indian J Pediatr. 2004,71(5):453-5.
[19] Salo J,Lehenkari P, Mulari M,et al.Removal of osteoclast bone resorption products by transcytosis. Science, 1997, 276(5310):266-269.
[20] Nesbitt S, Horton M.Trafficking of matrix collagens through bone-resorbing osteoclasts. Science, 1997, 276(5310):266-9.
[21] McHugh K, Hodivala-Dilke K, Zheng M,et al.Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts.J Clin Invest. 2000,105 (4):433-40.
[22] Hughes D, Dai A,Tiffee J,et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med.1996,2(10):1132-6.
[23] Kameda T,Mano H ,Yuasa T,et al . Estrogen inhibits bone resorption by directly inducing apoptosis of the bone2resorbing osteoclasts. J Exper Med ,1997,186: 489-495.
[24] Mano H ,Yuasa T, Kameda T,et al . Mammalian mature osteoclasts as estrogen target cells. Biochem Biophys Res Commun , 1996 , 223 :637-642.
[25] Vidal O , Kindblom L G, Ohlsson C. Expression and localization of estrogen receptor-beta in murine and human bone. J Bone Miner Res ,1999 ,14 :923-929.
[26] Hoyland JA , Mee AP , Baird P , et al. Demonstration of estrogen receptor mRNA in bone using in situ reverse-transcriptase polymerase chain reaction. Bone, 1997 ,20 :87-92.
[27] Nakagawa N , Kinosaki M , Yamaguchi K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun , 1998 ,253 :395-400.
[28]廖二元,周后德,邓小戈,等.雌二醇对成骨细胞护骨素基因表达的影响.中华内分泌代谢杂志,2001,17:2422245.
[29] Bord S , Ireland DC , Beavan SR , et al. The effects of estrogen on osteoprotegerin,RANKL, and estrogen receptor expression in human osteoblasts. Bone, 2003,32:136-141.
[30] Ikeda T , Utsuyama M , Hirokawa K. Expression profiles of receptor activator of nuclear factor kappaB ligand , receptor activator of nuclear factor kappaB , and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. J Bone Miner Res , 2001 ,16 :1416-1425.
[31] Shevde NK, Bendixen AC , Dienger KM , et al. Estrogens suppress RANKligand2induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA,2000,97: 7829-7834.
[32]王运林,廖二元,向光大,等.17β-雌二醇对人破骨样细胞RANK、CKmRNA表达的作用.中华内分泌代谢杂志.2004,20(6):556-558.
[33] Bord S, Ireland DC, Beavan SR, et al. The effects of estrogen on osteoprotegerin, RANKL, and estrogen recep tor exp ression in human osteoblasts[J].Bone, 2003, 32:136-141.
[34] Chen JR, Haley RL, Hidestrand M, et al. Estradiol Protects against ethanol2induced bone loss by inhibiting up-regulation of receptor activator of nuclear factor-{ kappa}B ligand in osteoblasts[J]. J Pharmacol Exp Ther,2006, 319:1182-1190.
[35] Chen W,Wong M.Genistein modulates the effects of parathyroid hormone in human osteoblastic SaOS-2 cells[J]. Br J Nutr,2006, 95:1039-1047.
[36] Hofbauer LC, Khosla S, Dunstan CR, et al. Estrogen stimulates gene exp ression and p rotein p roduction of osteop rotegerin in human osteoblastic cells [J]. Endocrinology,1999,140: 4367-4370.
[37] Liao EY, Luo XH, Su X. Comparison of the effects of 17beta-E2 and progesterone on the exp ression of osteop rotegerin in normal human osteoblast-like cells[J].J Endocrinol Invest, 2002,25:785-790.
[38]唐晓琳,孟焕新,张立等.17-β雌二醇对人牙周膜细胞骨向分化时核因子κB受体激动子配体和骨保护因子表达的影响.北京大学学报(医学版). 2007,39(1):50-53.
[39]鲁道海,张忠民,陈映红.雌激素对体外培养破骨细胞功能的影响.中华老年医学杂志.2000,19(6):431-434.
[40] Russell RG. Bisphosphonates: from bench to bedside[J]. Ann N Y AcadSci.2006, 106(8):367-40l.
[41] Ebetino F, Bayless A, Amburgey J, et al.Elucidation of a pharmacophore for the bisphosphonate mechanism of bone resorptive activity[J].Phosphorus Sulfur Silion 1996,109(110): 217-220.
[42] Van Beek E, Lowik C, Ebetino F,et al.Binding and antiresorptive properties of heterocycle-containing bisphophonate analogs: structure-activity trlationships[J]. Bone 1998,23:437-442.
[43] Geddes A, Souza S, Ebetino F, et al. Bisphosphonates:structure-activity relationships and therapeutic implcations.Bone[J].Miner Res,1994,8:265-306.
[44] Watts N, Harris S, Genant H,et al.Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990, 12;323(2):73-9.
[45] Frith J, Rogers M. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro[J]. J Bone Miner Res,2003, 18: 204-212.
[46] Selander K, Lehenkari P, Vaananen H. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts[J].Calcif Tiss Int, 1994,55: 368-375.
[47] Masarachia P,Weinreb M,Balena R,et al.Mechanism of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones[J].Bone, 1996, 19:281-290.
[48] Murakami H,Takahashi N,Sasaki T,et al.A possible mechanism of the specific action of bisphosphonates on osteoclasts:tiludronate preferentially affects polarized osteoclasts having ruffled borders[J]. Bone 1995,17:137-144.
[49] Hughes D,Wright K,et al.Bisphosphonate promote apoptosis in murine osteoclasts in vitro and in vivo[J].J Bone Miner Res 1995,10:1478-1487
[50] Pandy R,Quinn J,Sabokbar A,et a1. Bispbosphonate inhibition of bone resorption by particulate biomaterial associated macrophages[J].Acta Orthop Scand,1996,67:221-228.
[51]陈明,郑琼,方真华,等.阿伦膦酸钠对骨髓生成破骨细胞及骨吸收作用的影响.中国矫形外科杂志.2008,16(4):282-284.
[52] Arima N,Kajj Y,Kawakami K,et al.Direct effects of incadronate disodium on osteoclasts originated from human peripheral blood mononuclear cells[J].J Bone Miner Res2000,15(supple SU415):S432.
[53] Compston J.The therapeutic use of bisphosphonates.BMJ.1994, 309(6956): 711 -5.
[54]王莉,胡玮,白人骁等.二膦酸盐类药物治疗妇女绝经后骨质疏松症的疗效观察.中华骨科杂志,2001,21:526-528.
[55] Pols H, Felsenberg D, Hanley D,et al. Multinational,placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass:results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int.1999;9(5):461-8.
[56] Black D, Thompson D, Bauer D,et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000; 85(11):4118-24.
[57]张秀珍,宋利格,李红等.阿伦膦酸钠对绝经后骨质疏松症患者骨密度、细胞因子及骨代谢指标的影响.中华内科杂志.2006,45(7):565-568.
[58]张秀珍,韩峻峰,钱国峰.降钙素对体外培养破骨细胞功能的影响.中华内分泌代谢杂志.2004,20(2):58-160.
[59] Cornish J , Callon KE , Bava U , et al. Effects of calcitonin , amylin ,and calcitonin gene-related peptide on osteoclast development. Bone,2001, 29: 162-168.
[60] Nicholson GC , Moseley JM , Sexton PM , et al. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest, 1986,78:3552360.
[61]章振林,孟迅吾,周学瀛,等.北京地区汉族妇女维生素D受体基因和降钙素受体基因多态性与骨密度的关系.中华内分泌代谢杂志,2002,18:90-94.
[62] Takahashi S, Goldring S, Katz M,et al. Down regulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest, 1995,95:1672171.
[63] Nakamura M, Yang Q, Gouda T,et al. Loss of calcitonin binding in rat is not related to calcitonin receptor gene abnormality. Biochem Biophys Res Commun, 2001,284:1184-1188.
[64] Wang YX, Wang HT, L iu TW. New research progress of rheumatism arthritis curative[J]. Pract Pharm Clin Rem, 2006,9:253-254.
[65] Eklund KK, Leirisalo2Repo M, Ranta P, et al. Serum IL-1beta levels are associated with the presence of erosions in recent onset rheumatoid arthritis [J]. Clin Exp Rheumatol,2007, 25: 684-689.
[66] Lu Y, Shao CS, Shen JG, et al. The immune regulation mechanism of treatment of rheumatoid arthritis with methotrexate [J]. Chin JMod App l Pharm(中国现代应用药学), 2002,19:189-191.
[67] Iagnocco A, Cerioni A, Coari G, et al. Intra-articular methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis: a clinical and sonographic study[J].Clin Rheumatol, 2006, 25: 159-163.
[68]李萍,王霖,王文杰.甲氨蝶呤对破骨细胞的作用及机制研究.药学学报.2008,43(10):1025-1031.
[69] Du W, Chen Y, Tong P, et al. Study p rogress of osteoclastes cultured in vitro differentiation factor and its mechanism [J]. Mod J Integr Tradit Chin West Med (现代中西医结合杂志), 2006, 15: 258-260.
[70] Rossa C, Ehmann K, L iuM, et al. MKK3 /6-p38MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromalcells [J]. J Interferon Cytokine Res, 2006, 26: 719-729.
[71] Liu QH, Teng Y, Wang H, et al. Effects ofmethotrexate (MTX) on cell proliferation and cell cycling of synovial fibroblasts in patients with rheumatoid arthritis [J].China J Mod Med (中国现代医学杂志), 2004, 14: 8-10.
[72] Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system[J]. Cell. 2002; 111(3):305-317.
[73] Aitken SJ, Landao-Bassonga E, Ralston SH, et al.β2-Adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms[J]. Arch Biochem Biophys. 2009;482(1-2):96-103.
[74] Takeuchi T, Tsuboi T, Arai M, et al. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells[J]. Biochemical Pharmacology.2001;61(5):579 -586.
[75] Arai M, Nagasawa T, Koshihara Y, et al. Effects ofβ-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells[J].Biochim Biophys Acta. 2003;1640(2-3):137-142.
[76] Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system[J]. Cell. 2002; 111(3):305-317.
[77] Bonnet N, Laroche N, Vico L, et al.Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats[J].J Pharmacol Exp Ther. 2006; 318(3):1118-1127.
[78] Bonnet N, Gadois C, McCloskey E,et al.Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture[J].Bone.2007;40(5):1209-1216.
[79] Pasco JA, Henry MJ, Sanders KM, et al. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density[J]. J Bone Miner Res.2004; 19(1):19-24.
[80] Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study[J]. J Hypertens. 2006; 24(3):581-189.
[81] Reid IR, Gamble GD, Grey AB,et al.Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures[J].J Bone Miner Res.2005;20(4):613–618.
[82] Rousselle A, Heymann D. Osteoclastic acidification pathways during bone resorption[J].Bone.2002,30(4):533-540.
[83] Baron R, T souderos Y. In vitro effects of S1291122 on o steoclast function and bone marrow macrophage differentiation [J]. Eur J Pharmaco, 2002, 450 (1): 11-17.
[84] Lehenkari P, Hentunen T, Laitala-L einonen T, et al. Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca2+ [J]. Exp Cell Res,1998,242 (1):128-137.
[85]李建军,景元海,王宏等.Ⅱ型碳酸酐酶对破骨细胞性骨吸收的影响.吉林大学学报(医学版).2004,30(1):11-14.
[86] Biskobing D, Fan D. Acid pH increases carbonic anhydrase II and calcitonin receptor mRNA expression in mature o steoclasts[J]. Calcif T issue Int, 2000,67 (2):178-183.
[87] SacoT, Foged N, Delaisse J. The migrations of Purified osteoclasts through collagen is inhibited by matrix metalloproteinase inhibitors[J].J Bone Miner Res, 1998, 59: 13.
[88] HuangW, Lau A, Daniels L, et al. Detection of estrogen receptor alpha, carbonic anhydrase II and tartrate-resistant acid phosphatase mRNA s in putative mononuclear osteoclast precursor cells of neonatal rats by fluorescence in situ hybridization [J]. J Mol Endocrinol, 1998, 20 (2) : 211-219.
[89] Laitala-L einonen T, Lowik C, Papapoulos S, et al. Inhibition of intravacuolar acidification by antisense RNA decreases osteoclast differentiation and bone resorption in vitro [J]. J Cell Sci,1999,112( Pt21):3657-3666.
[90] Davies G, Huster W, Plouffe L ,et al. Adverse event s reported by postmenopausal women in controlled trials with raloxifene[J]. J Obstet Gynecol,1999,93:558.
[91] Barrett-Connor E , Grady D. Raloxifene and cardiovascular event s in osteoporotic postmenopausal women: four-year result s from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial[J]. JAMA,2002,287 :847.
[92]聂晶,卢良华,孙军.预防和治疗骨质疏松症的有效药物依普黄铜[J].中国现代应用药学杂志,2002,19(1):71.
[2] Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system[J]. Cell. 2002; 111(3):305-317.
[3] Chambers T, Magnus C. Calcitonin alters behavior of isolated osteoclasts[J]. J Pathol.1982;136(1):27-39.
[4]李斌斌,于世凤,庞淑珍.两种破骨细胞培养方法的比较及其吸收骨质的动态观察[J].北京大学学报(医学版). 2005; 37(5):536-541.
[5] Takeuchi T,Tsuboi T,Arai M, et al. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells[J]. Biochemical Pharmacology. 2001;61(5):579-586.
[6] Roodman G. Cell biology of the osteoclast[J]. Exp Hematol,1999,27:1229-1241.
[7] Zhao Q, Shao J, Chen W,et al. Osteoclast differentiation and gene regulation. Front Biosci. 2007;12:2519-2529.
[8]赵媛,王正东.骨组织工程种子细胞的研究及应用进展.沈阳医学院学报.2007,9(1):56-59.
[9] Gangji V, Hauzeur J, Schoutens A,et al. Abnormalities in the replicative capacity of osteoblastic cells in the proximal femur of patients with osteonecrosis of the femoral head. J Rheumatol.2003,30(2):348-351.
[10] Hofbauer L, Dunstan C, Spelsberg T,et al. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun.1998;250 (3):776-781
[11] Thirunavukkarasu K, Miles R, Halladay D, Stimulation of osteoprotegerin (OPG)gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem.2001;276 (39):36241-36250.
[12] Lee S, Lorenzo J. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology.1999;140 (8):3552-3561.
[13] Ma Y, Cain R, Halladay D,et al. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology.2001;142 (9):4047-4054.
[14] Amano S, Arai M, Goto S,et al. Inhibitory effect of NPY on isoprenaline-induced osteoclastogenesis in mouse bone marrow cells. Biochim Biophys Acta. 2007; 1770(6):966-973.
[15] Kaczmarczyk-Sedlak I, Janiec W. Effects of catecholamines on blood pressure in the long bone marrow cavity in rats with bisphosphonate-induced osteopetrosis. Pharmacol Rep.2005;57(5):623-634.
[16] Kondo H, Nifuji A, Takeda S,et al. Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system. J Biol Chem.2005;280 (34):30192-30200.
[17] Ishizuka K, Hirukawa K, Nakamura H,et al. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. Neurosci Lett.2005,379(1):47-51.
[18] Bab I, Zimmer A. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol.2008 Jan;153(2):182-188.
[19] Bab I. Regulation of skeletal remodeling by the endocannabinoid system. Ann NY Acad Sci. 2007; 1116:414-422.
[20] Bonnet N,Laroche N,Vico L,et al.Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats. J Pharmacol Exp Ther.2006;318 (3):1118-1127.
[21] Togari A. Increased bone resorption by sympathetic nervous activity. Clin Calcium.2006;16(2):298-303.
[22] Cohen MM Jr. Role of leptin in regulating appetite, neuroendocrine function, and bone remodeling. Am J Med Genet A.2006;140(5):515-24.
[23] Tam J, Ofek O, Fride E,et al. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol.2006;70(3):786 -92.
[24] Pogoda P, Egermann M, Schnell J,et al. Leptin inhibits bone formation not only in rodents, but also in sheep. J Bone Miner Res.2006;21(10):1591-1599.
[25] Kim J, Jeong D, Kang H,et al. Osteoclast precursors display dynamic metabolic shifts toward accelerated glucose metabolism at an early stage of RANKL- stimulated osteoclast differentiation. Cell Physiol Biochem.2007;20(6):935-946.
[26] Lorenzo J. Osteoclast precursor cells. Adv Exp Med Biol.2007; 602:77-82.
[27] Moore R,Smith C,Bailey C,et al.Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture[J].Bone Miner, 1993;23:301-315.
[28] Kellenberger S, Muller K, Richener H,et al.Formoterol and isoproterenol induce c-fos gene expression in osteoblast-like cells by activating beta-adrnergic receptors[J]. Bone,1998;22(5):471-478.
[29] Bjurholm A, Kreicbergs A, Schultzberg M, Lerner UH. Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106-01, ROS 17/2.8, MC3T3-E1, and Saos-2) and primary bone cells[J].Bone Miner Res.1992;7(9):1011-1009.
[30] Greenfield E, Horowitz M, Lavish S. Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction[J].Biol Chem. 1996;271(18):10984-10989.
[31] Aitken S, Landao-Bassonga E, Ralston S, et al.β2-Adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms [J].Arch Biochem Biophys. 2009;482(1-2):96-103.
[32] Ducy P, Amling M, Takeda S et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass[J].Cell.2000;100(2):197-207.
[33] Arai M, Nagasawa T, Koshihara Y, et al. Effects ofβ-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells[J].Biochim Biophys Acta. 2003;1640(2-3):137-142.
[34] Bonnet N, Gadois C, McCloskey E,et al.Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture[J].Bone.2007;40(5):1209-1216.
[35] Pasco J, Henry M, Sanders K, et al. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density[J]. J Bone Miner Res. 2004; 19(1):19-24.
[36] Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study[J]. J Hypertens. 2006 ; 24(3):581-189.
[37] Schlienger R, Kraenzlin M, Jick S,et al. Use of beta-blockers and risk of fractures[J].JAMA. 2004; 292(11):1326-1332.
[38] Reid I, Gamble G, Grey A,et al.Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures[J].J Bone Miner Res.2005;20(4):613–618.
[1] Roodman G. Cell biology of the osteoclast[J]. Exp Hematol,1999,27:1229-1241.
[2] Zhao Q, Shao J, Chen W,et al. Osteoclast differentiation and gene regulation. Front Biosci. 2007;12:2519-29.
[3] Roberto Pacifici. Editorial:Cytokines, Estrogen,and Postmenopausal Osteoporosis -The Second Decade [J]. Endocrinology,1998,139(6):2659-2661.
[4] Udagawa N, Takahashi N, Akatsu T,et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A. 1990,87(18):7260-4.
[5] Jimi E,Nakamura I,Amano H,et al. Oeteoclast functions is activated by osteoblastic cells through a mechanism involving cell-to-cell contact [J]. Endocrinology,1996,137(5):2187～2190.
[6] Lacey D, Timms E, Tan H,et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.Cell,1998,93(2):309-319.
[7] Simonet W, Lacey D, Dunstan C,et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell,1997,89(2):309-19.
[8] Hofbauer L, Schoppet M.Clinical implications of the osteoprotegering/RANKL/RANK system for bone and vascular diseases. JAMA, 2004,292(4):490-5.
[9] Ramalho A, Jullienne A, Couttet P,et al. Effect of ostradiol on cytokine production in immortalized human marrow stromal cell lines. Cytokine. 2001,16 (4):126-30.
[10] Udagawa N. The mechanism of osteoclast differentiation from macrophages: possible roles of T lymphocytes in osteoclastogenesis. J Bone Miner Metab.2003; 21(6):337-43.
[11] Lee S, Lorenzo J. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation . Endocrinology.1999, 140(8): 3552-61.
[12] Kitazawa R,Kitazawa S, Maeda S. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene . Biochim Biophys Acta .1999,1445(1): 134-41.
[13] Rodan S, Rodan G. Integrin function in osteoclasts. J Endocrinol, 1997, 154: S47-S56.
[14] Vaananen H, Horton M.The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J Cell Sci.1995,108 ( Pt 8):2729-32.
[15] Stenbeck G, Horton M.A new specialized cell-matrix interaction in actively resorbing osteoclasts. J Cell Sci. 2000,113 ( Pt 9):1577-87.
[16] Schlesinger P, Blair H, Teitelbaum S, et al.Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption. J Biol Chem. 1997,272(30):18636-43.
[17] Xiong W, Feng X. PYK2 and FAK in osteoclasts. Front Biosci. 2003,8: d1219-1226.
[18] Singh A, Kaur A, Anand N,et al. Pyknodysostosis: visceral manifestations and simian crease. Indian J Pediatr. 2004,71(5):453-5.
[19] Salo J,Lehenkari P, Mulari M,et al.Removal of osteoclast bone resorption products by transcytosis. Science, 1997, 276(5310):266-269.
[20] Nesbitt S, Horton M.Trafficking of matrix collagens through bone-resorbing osteoclasts. Science, 1997, 276(5310):266-9.
[21] McHugh K, Hodivala-Dilke K, Zheng M,et al.Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts.J Clin Invest. 2000,105 (4):433-40.
[22] Hughes D, Dai A,Tiffee J,et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med.1996,2(10):1132-6.
[23] Kameda T,Mano H ,Yuasa T,et al . Estrogen inhibits bone resorption by directly inducing apoptosis of the bone2resorbing osteoclasts. J Exper Med ,1997,186: 489-495.
[24] Mano H ,Yuasa T, Kameda T,et al . Mammalian mature osteoclasts as estrogen target cells. Biochem Biophys Res Commun , 1996 , 223 :637-642.
[25] Vidal O , Kindblom L G, Ohlsson C. Expression and localization of estrogen receptor-beta in murine and human bone. J Bone Miner Res ,1999 ,14 :923-929.
[26] Hoyland JA , Mee AP , Baird P , et al. Demonstration of estrogen receptor mRNA in bone using in situ reverse-transcriptase polymerase chain reaction. Bone, 1997 ,20 :87-92.
[27] Nakagawa N , Kinosaki M , Yamaguchi K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun , 1998 ,253 :395-400.
[28]廖二元,周后德,邓小戈,等.雌二醇对成骨细胞护骨素基因表达的影响.中华内分泌代谢杂志,2001,17:2422245.
[29] Bord S , Ireland DC , Beavan SR , et al. The effects of estrogen on osteoprotegerin,RANKL, and estrogen receptor expression in human osteoblasts. Bone, 2003,32:136-141.
[30] Ikeda T , Utsuyama M , Hirokawa K. Expression profiles of receptor activator of nuclear factor kappaB ligand , receptor activator of nuclear factor kappaB , and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. J Bone Miner Res , 2001 ,16 :1416-1425.
[31] Shevde NK, Bendixen AC , Dienger KM , et al. Estrogens suppress RANKligand2induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA,2000,97: 7829-7834.
[32]王运林,廖二元,向光大,等.17β-雌二醇对人破骨样细胞RANK、CKmRNA表达的作用.中华内分泌代谢杂志.2004,20(6):556-558.
[33] Bord S, Ireland DC, Beavan SR, et al. The effects of estrogen on osteoprotegerin, RANKL, and estrogen recep tor exp ression in human osteoblasts[J].Bone, 2003, 32:136-141.
[34] Chen JR, Haley RL, Hidestrand M, et al. Estradiol Protects against ethanol2induced bone loss by inhibiting up-regulation of receptor activator of nuclear factor-{ kappa}B ligand in osteoblasts[J]. J Pharmacol Exp Ther,2006, 319:1182-1190.
[35] Chen W,Wong M.Genistein modulates the effects of parathyroid hormone in human osteoblastic SaOS-2 cells[J]. Br J Nutr,2006, 95:1039-1047.
[36] Hofbauer LC, Khosla S, Dunstan CR, et al. Estrogen stimulates gene exp ression and p rotein p roduction of osteop rotegerin in human osteoblastic cells [J]. Endocrinology,1999,140: 4367-4370.
[37] Liao EY, Luo XH, Su X. Comparison of the effects of 17beta-E2 and progesterone on the exp ression of osteop rotegerin in normal human osteoblast-like cells[J].J Endocrinol Invest, 2002,25:785-790.
[38]唐晓琳,孟焕新,张立等.17-β雌二醇对人牙周膜细胞骨向分化时核因子κB受体激动子配体和骨保护因子表达的影响.北京大学学报(医学版). 2007,39(1):50-53.
[39]鲁道海,张忠民,陈映红.雌激素对体外培养破骨细胞功能的影响.中华老年医学杂志.2000,19(6):431-434.
[40] Russell RG. Bisphosphonates: from bench to bedside[J]. Ann N Y AcadSci.2006, 106(8):367-40l.
[41] Ebetino F, Bayless A, Amburgey J, et al.Elucidation of a pharmacophore for the bisphosphonate mechanism of bone resorptive activity[J].Phosphorus Sulfur Silion 1996,109(110): 217-220.
[42] Van Beek E, Lowik C, Ebetino F,et al.Binding and antiresorptive properties of heterocycle-containing bisphophonate analogs: structure-activity trlationships[J]. Bone 1998,23:437-442.
[43] Geddes A, Souza S, Ebetino F, et al. Bisphosphonates:structure-activity relationships and therapeutic implcations.Bone[J].Miner Res,1994,8:265-306.
[44] Watts N, Harris S, Genant H,et al.Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990, 12;323(2):73-9.
[45] Frith J, Rogers M. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro[J]. J Bone Miner Res,2003, 18: 204-212.
[46] Selander K, Lehenkari P, Vaananen H. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts[J].Calcif Tiss Int, 1994,55: 368-375.
[47] Masarachia P,Weinreb M,Balena R,et al.Mechanism of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones[J].Bone, 1996, 19:281-290.
[48] Murakami H,Takahashi N,Sasaki T,et al.A possible mechanism of the specific action of bisphosphonates on osteoclasts:tiludronate preferentially affects polarized osteoclasts having ruffled borders[J]. Bone 1995,17:137-144.
[49] Hughes D,Wright K,et al.Bisphosphonate promote apoptosis in murine osteoclasts in vitro and in vivo[J].J Bone Miner Res 1995,10:1478-1487
[50] Pandy R,Quinn J,Sabokbar A,et a1. Bispbosphonate inhibition of bone resorption by particulate biomaterial associated macrophages[J].Acta Orthop Scand,1996,67:221-228.
[51]陈明,郑琼,方真华,等.阿伦膦酸钠对骨髓生成破骨细胞及骨吸收作用的影响.中国矫形外科杂志.2008,16(4):282-284.
[52] Arima N,Kajj Y,Kawakami K,et al.Direct effects of incadronate disodium on osteoclasts originated from human peripheral blood mononuclear cells[J].J Bone Miner Res2000,15(supple SU415):S432.
[53] Compston J.The therapeutic use of bisphosphonates.BMJ.1994, 309(6956): 711 -5.
[54]王莉,胡玮,白人骁等.二膦酸盐类药物治疗妇女绝经后骨质疏松症的疗效观察.中华骨科杂志,2001,21:526-528.
[55] Pols H, Felsenberg D, Hanley D,et al. Multinational,placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass:results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int.1999;9(5):461-8.
[56] Black D, Thompson D, Bauer D,et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000; 85(11):4118-24.
[57]张秀珍,宋利格,李红等.阿伦膦酸钠对绝经后骨质疏松症患者骨密度、细胞因子及骨代谢指标的影响.中华内科杂志.2006,45(7):565-568.
[58]张秀珍,韩峻峰,钱国峰.降钙素对体外培养破骨细胞功能的影响.中华内分泌代谢杂志.2004,20(2):58-160.
[59] Cornish J , Callon KE , Bava U , et al. Effects of calcitonin , amylin ,and calcitonin gene-related peptide on osteoclast development. Bone,2001, 29: 162-168.
[60] Nicholson GC , Moseley JM , Sexton PM , et al. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest, 1986,78:3552360.
[61]章振林,孟迅吾,周学瀛,等.北京地区汉族妇女维生素D受体基因和降钙素受体基因多态性与骨密度的关系.中华内分泌代谢杂志,2002,18:90-94.
[62] Takahashi S, Goldring S, Katz M,et al. Down regulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest, 1995,95:1672171.
[63] Nakamura M, Yang Q, Gouda T,et al. Loss of calcitonin binding in rat is not related to calcitonin receptor gene abnormality. Biochem Biophys Res Commun, 2001,284:1184-1188.
[64] Wang YX, Wang HT, L iu TW. New research progress of rheumatism arthritis curative[J]. Pract Pharm Clin Rem, 2006,9:253-254.
[65] Eklund KK, Leirisalo2Repo M, Ranta P, et al. Serum IL-1beta levels are associated with the presence of erosions in recent onset rheumatoid arthritis [J]. Clin Exp Rheumatol,2007, 25: 684-689.
[66] Lu Y, Shao CS, Shen JG, et al. The immune regulation mechanism of treatment of rheumatoid arthritis with methotrexate [J]. Chin JMod App l Pharm(中国现代应用药学), 2002,19:189-191.
[67] Iagnocco A, Cerioni A, Coari G, et al. Intra-articular methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis: a clinical and sonographic study[J].Clin Rheumatol, 2006, 25: 159-163.
[68]李萍,王霖,王文杰.甲氨蝶呤对破骨细胞的作用及机制研究.药学学报.2008,43(10):1025-1031.
[69] Du W, Chen Y, Tong P, et al. Study p rogress of osteoclastes cultured in vitro differentiation factor and its mechanism [J]. Mod J Integr Tradit Chin West Med (现代中西医结合杂志), 2006, 15: 258-260.
[70] Rossa C, Ehmann K, L iuM, et al. MKK3 /6-p38MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromalcells [J]. J Interferon Cytokine Res, 2006, 26: 719-729.
[71] Liu QH, Teng Y, Wang H, et al. Effects ofmethotrexate (MTX) on cell proliferation and cell cycling of synovial fibroblasts in patients with rheumatoid arthritis [J].China J Mod Med (中国现代医学杂志), 2004, 14: 8-10.
[72] Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system[J]. Cell. 2002; 111(3):305-317.
[73] Aitken SJ, Landao-Bassonga E, Ralston SH, et al.β2-Adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms[J]. Arch Biochem Biophys. 2009;482(1-2):96-103.
[74] Takeuchi T, Tsuboi T, Arai M, et al. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells[J]. Biochemical Pharmacology.2001;61(5):579 -586.
[75] Arai M, Nagasawa T, Koshihara Y, et al. Effects ofβ-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells[J].Biochim Biophys Acta. 2003;1640(2-3):137-142.
[76] Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system[J]. Cell. 2002; 111(3):305-317.
[77] Bonnet N, Laroche N, Vico L, et al.Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats[J].J Pharmacol Exp Ther. 2006; 318(3):1118-1127.
[78] Bonnet N, Gadois C, McCloskey E,et al.Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture[J].Bone.2007;40(5):1209-1216.
[79] Pasco JA, Henry MJ, Sanders KM, et al. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density[J]. J Bone Miner Res.2004; 19(1):19-24.
[80] Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study[J]. J Hypertens. 2006; 24(3):581-189.
[81] Reid IR, Gamble GD, Grey AB,et al.Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures[J].J Bone Miner Res.2005;20(4):613–618.
[82] Rousselle A, Heymann D. Osteoclastic acidification pathways during bone resorption[J].Bone.2002,30(4):533-540.
[83] Baron R, T souderos Y. In vitro effects of S1291122 on o steoclast function and bone marrow macrophage differentiation [J]. Eur J Pharmaco, 2002, 450 (1): 11-17.
[84] Lehenkari P, Hentunen T, Laitala-L einonen T, et al. Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca2+ [J]. Exp Cell Res,1998,242 (1):128-137.
[85]李建军,景元海,王宏等.Ⅱ型碳酸酐酶对破骨细胞性骨吸收的影响.吉林大学学报(医学版).2004,30(1):11-14.
[86] Biskobing D, Fan D. Acid pH increases carbonic anhydrase II and calcitonin receptor mRNA expression in mature o steoclasts[J]. Calcif T issue Int, 2000,67 (2):178-183.
[87] SacoT, Foged N, Delaisse J. The migrations of Purified osteoclasts through collagen is inhibited by matrix metalloproteinase inhibitors[J].J Bone Miner Res, 1998, 59: 13.
[88] HuangW, Lau A, Daniels L, et al. Detection of estrogen receptor alpha, carbonic anhydrase II and tartrate-resistant acid phosphatase mRNA s in putative mononuclear osteoclast precursor cells of neonatal rats by fluorescence in situ hybridization [J]. J Mol Endocrinol, 1998, 20 (2) : 211-219.
[89] Laitala-L einonen T, Lowik C, Papapoulos S, et al. Inhibition of intravacuolar acidification by antisense RNA decreases osteoclast differentiation and bone resorption in vitro [J]. J Cell Sci,1999,112( Pt21):3657-3666.
[90] Davies G, Huster W, Plouffe L ,et al. Adverse event s reported by postmenopausal women in controlled trials with raloxifene[J]. J Obstet Gynecol,1999,93:558.
[91] Barrett-Connor E , Grady D. Raloxifene and cardiovascular event s in osteoporotic postmenopausal women: four-year result s from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial[J]. JAMA,2002,287 :847.
[92]聂晶,卢良华,孙军.预防和治疗骨质疏松症的有效药物依普黄铜[J].中国现代应用药学杂志,2002,19(1):71.